Latest News

Germany to pump €1bn into breakthrough innovation

German Research Minister Anja Karliczek and Economics Minister Peter Altmaier make a joint statement on the founding of the Agency for Jump Innovations following the meeting of the Federal Cabinet. © BMBF / Hans-Joachim Rickel


by tg

Germany’s government announced that it will create an agency for breakthrough ("jump") innovation to foster technology transfer of risky research projects with high market potential into products.

The German agency precede EU plans to create a similar EU agency within its next research framework programme starting in 2021. The agency will be funded with roughly €1bn over 10 years.

The move is intented to keep value creation in Germany.  The idea for such an agency is lent from the US agency DARPA (Defense Advanced Research Projects Agency), which was founded by President Dwight D. Eisenhower in the 1950ies to support commercialisation of groundbreaking inventions such as the Internet, GPS or driverless vehicles. Besides Germany, Sweden and Switzerland have already established innovation agencies for non-military purposes. 

The German agency is set to start next year. According to Germany’s minister for economics, Peter Altmaier, a first call will seek for 3 to 4 promising artificial intelligence projects.

New checkpoint inhibitor on the block

In Nature, Josef Penninger from IMBA and co-workers from six nations report that tetrahydrobiopterin (BH4, THB), a well-known co-factor of...

Nanobots heading to eye delivery

Traditional  methods of intravitreal delivery of therapeutic agents rely on the random, passive diffusion of molecules, which do not allow for...

TES Pharma presents new treatment approach towards AKI and NALFD

Italian TES Pharma s.r.l. (Perugia) has presented preclinical results of TES-991 and a backup compound, both enhancers of mitochondrial...

Staten Biotechnology in $430m deal with Novo Nordisk

Under the agreement, Dutch Staten Biotechnology B.V. and Novo Nordisk A/S will collaborate to co-develop Staten's preclinical dyslipidemia...

Driver of GVHD after blood stem cell transplantation identified

The results of the team headed by Sonia Tugues from ETH Zürich solve a paradox in the field of allogenic blood stem cell...

Companies at EFIB set to drive the bioeconomy

Company presentations at the 11th European Forum of Industrial Biotechnology and the Bioeconomy (EFIB, 16-18 October 2018) clearly demonstrated that...

Sanofi and Denali Therapeutics ink €1.125bn deal in neurology/inflammation

Denali Therapeutics Inc.'s small molecule drug candidates DNL747 and DNL758 target the receptor-interacting serine/threonine-protein kinase 1...